Bio Plus Co., Ltd (KOSDAQ:099430)

South Korea · Delayed Price · Currency is KRW

3,000.00

-20.00 (-0.66%)

Nov 13, 2026, 3:30 PM KST

Market Cap	184.62B -48.6%
Revenue (ttm)	99.15B +11.2%
Net Income	13.85B -14.6%
EPS	156.28 -35.3%
Shares Out	61.54M
PE Ratio	19.20
Forward PE	n/a
Dividend	70.00 (2.33%)
Ex-Dividend Date	Dec 29, 2026

Volume	129,146
Open	3,020.00
Previous Close	3,020.00
Day's Range	3,000.00 - 3,120.00
52-Week Range	2,865.00 - 6,430.00
Beta	0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2003

Employees 161

Stock Exchange KOSDAQ

Ticker Symbol 099430

Full Company Profile

Financial Performance

In 2025, Bio Plus's revenue was 90.90 billion, an increase of 36.87% compared to the previous year's 66.41 billion. Earnings were 15.00 billion, an increase of 6.01%.

Financial Statements